Leflunomide serves as a disease-modifying antirheumatic drug (DMARD). Pyrimidine synthesis pathways are inhibited to regulate overactive immune cell proliferation involved in chronic joint tissue damage and inflammation.
Targeting overactive immune cells, this medication belongs to the pyrimidine synthesis inhibitor class and primarily reduces inflammatory activity in chronic joint disease. By limiting the proliferation of activated lymphocytes, it helps modulate the immune response that drives pain and swelling. The active compound is the key ingredient in products marketed under the name Arava. In Singapore, it is recognised as an option for managing autoimmune joint conditions.
Formulated for oral use, the ingredient appears in tablet form within the brand Arava and in several generic equivalents approved by the Health Sciences Authority. Tablets are scored to allow easy splitting when dose adjustments are required. Both brand-name and generic versions meet the same regulatory standards, though packaging and cost may differ. Patients receive the medication through pharmacies following a qualified healthcare professional’s prescription.
Interfering with immune cell activation, the drug is employed to address rheumatoid arthritis when other agents have proven insufficient. It also assists individuals with psoriatic arthritis, helping to alleviate skin and joint symptoms. Some clinicians consider it for adult patients with severe psoriasis who need systemic treatment. In rare cases, it may be part of a regimen for juvenile idiopathic arthritis after specialist evaluation. Overall, the substance is chosen for conditions where suppressing excessive immune activity improves quality of life.
Blocking an enzyme needed for building pyrimidine nucleotides, the compound slows the growth of rapidly dividing immune cells. This reduction curtails the cascade that leads to joint inflammation and tissue damage. The effect is gradual, often becoming noticeable after several weeks of consistent use. By limiting the supply of building blocks for DNA synthesis, the medication helps restore a more balanced immune environment.
Mild, temporary sensations such as stomach discomfort, headache, or a short-lived rash may appear during the first weeks of therapy. These effects usually lessen without medical intervention.
Rarely, patients experience severe liver injury, low blood cell counts, or lung inflammation that requires immediate medical attention. Prompt evaluation is essential if symptoms like jaundice, persistent fever, or unexplained breathlessness develop.
Pregnant individuals, those with known severe liver disease, and patients with a history of hypersensitivity to the substance should avoid its use. The medication is also unsuitable for people with active infections that could worsen under immune suppression.
Alcohol intake can amplify liver-related risks, so limiting consumption is advisable. Co-administration with certain antihypertensive agents, anticoagulants, or other immunosuppressants may alter effectiveness or safety; patients should refer to their medication’s insert for a complete interaction list.
Storing tablets at room temperature away from moisture preserves stability. Treatment duration varies: some patients require short-term courses for flare control, while others remain on therapy for many years to maintain disease stability. Different brands of Arava may have distinct tablet strengths, so pharmacists dispense the appropriate strength per the prescription. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This overview provides educational information about leflunomide and is not medical advice; individual medicines such as Arava differ in strength, formulation, and instructions; the provider assumes no liability for clinical application; patients should review their specific medication labeling and consult a qualified healthcare professional for personalized guidance.
